Viatris Inc.

Viatris Inc. is a global healthcare company that offers a broad portfolio of prescription brand drugs, generic drugs, complex generic drugs, and biosimilars. Its products cover therapeutic areas such as cardiovascular, central nervous system and anesthesia, dermatology, diabetes and metabolism, eye care, gastroenterology, immunology, oncology, and respiratory and allergy. Notable brands include Lyrica, Lipitor, Celebrex, Viagra, Creon, EpiPen Auto-Injector, and Wixela Inhub. The company also provides support services like diagnostic clinics, educational seminars, and digital tools to help patients manage their health. Viatris distributes its medicines in forms including oral solid doses, injectables, and complex dosage forms.

Viatris Inc. is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol VTRS. Its shares are traded in United States Dollars (USD). As a US-based company, its primary listing is on a major US exchange, providing liquidity and accessibility to investors globally.

Viatris operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. This means the company focuses on developing, manufacturing, and marketing both branded and generic pharmaceutical products, including complex generics and biosimilars. As a specialty and generic drug manufacturer, Viatris competes in markets for off-patent medications as well as differentiated therapies.

Viatris has a global presence, operating in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. The company is organized into four segments: Developed Markets, Greater China, JANZ (Japan, Australia, New Zealand), and Emerging Markets. This structure allows Viatris to tailor its product offerings and distribution strategies to diverse regional healthcare needs and regulatory environments.

Viatris generates revenue by selling a wide range of pharmaceutical products to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. Its portfolio includes both branded and generic drugs, complex generics, and biosimilars. The company also earns from support services like diagnostic clinics and digital health tools. Viatris has collaboration agreements, such as with Mapi Pharma Ltd. for long-acting glatiramer acetate depot products, to expand its pipeline. Revenue is diversified across therapeutic areas and geographic segments, with distribution through pharmaceutical wholesalers, retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies.